Skip to main content
Ralph Panos, MD, Pulmonology, Cincinnati, OH

Ralph Joseph Panos MD

Critical Care Medicine, Pleural Disease


Professor, Internal Medicine, University of Cincinnati College of Medicine

Join to view full profile
  • 222 Piedmont AvenueSuite 4000Cincinnati, OH 45219

  • Phone+1 513-475-8523

  • Fax+1 513-475-7327

Dr. Panos is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1990
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 1983 - 1987
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 1983

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2004 - 2028
  • PA State Medical License
    PA State Medical License 1997 - 2004
  • IL State Medical License
    IL State Medical License 1991 - 1999
  • CO State Medical License
    CO State Medical License 1990 - 1993
  • MD State Medical License
    MD State Medical License 1986 - 1987
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Arch Biopartners’ Therapy Candidate AB569 Receives US Patent for Treatment of Chronic Lung Infections
    Arch Biopartners’ Therapy Candidate AB569 Receives US Patent for Treatment of Chronic Lung InfectionsApril 6th, 2018
  • Veterans Affairs Hospital Introduces New Tele-ICU Technology
    Veterans Affairs Hospital Introduces New Tele-ICU TechnologyMarch 28th, 2018
  • Arch Biopartners’ Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial
    Arch Biopartners’ Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human TrialApril 13th, 2017

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: